Dentistry Products:

Colgate Duraphat 2800ppm Fluoride Toothpaste

  Overview   FAQs   Clinical research   Information   Indications  

Colgate Duraphat 2800ppm Fluoride Toothpaste
Sodium Fluoride 0.619% w/w (2800ppm F)

Distributors

spacer image
Distributor Name Phone URL
CTS 01737 765 400 www.cts-dental.com
Dental Directory 01376 500 222 www.dental-directory.co.uk
DHB 0845 601 7086 www.dhb.co.uk
Dent-O-Care 0208 459 7550 www.dentocare.co.uk
Henry Schein 08700 102 043 www.henryschein.co.uk
Survival 32 01189 516 161 -
 
1. Name of the Medicinal Product
Duraphat 2800 ppm Fluoride Toothpaste
2. Qualitative and Quantitative Composition
Sodium Fluoride 0.619 % w/w (2800 ppm F) For the full list of excipients, see section 6.1
3. Pharmaceutical Form
Toothpaste
Smooth White Paste
For dental use
4. Clinical Particulars
4.1 Therapeutic Indications
For the prevention and treatment of dental caries (coronal and root) in adults and children over 10 years.
4.2 Posology and Method of Administration
Posology Children under 10 years old: not recommended
Adults and children over 10 years old: Use daily instead of the normal toothpaste. The usual dosage is to apply a 1 cm line of paste across the head of a toothbrush and brush the teeth thoroughly for one minute morning and evening. Spit out after use; for best results do not drink or rinse for 30 minutes.
Elderly: use as for adults.
Method of administration For dental use
4.3 Contraindications
  • Hypersensitivity to the active substance(s) or to any of the excipients
  • Individuals with known sensitivities should consult their dentist before using
  • Not to be used in children under 10 years old
4.4 Special Warnings and Precautions for Use
Not to be swallowed.
4.5 Interactions with Other Medicinal Products and Other Forms of Interaction
None known.
4.6 Pregnancy and Lactation
Epidemiological studies in humans indicate that fluoride has no adverse effects in pregnancy or on the health of the foetus or newborn child.
No effects during pregnancy are anticipated, since systemic exposure to Sodium Fluoride is negligible. Duraphat 2800 Toothpaste can be used during pregnancy.
No effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-feeding woman to Sodium Fluoride is negligible. Duraphat 2800 Toothpaste can be used during breast-feeding.
4.7 Effects on Ability to Drive and Use Machines
Not applicable.
4.8 Undesirable Effects
When used as recommended there are no side effects.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9 Overdose
Symptoms:
In very high doses, fluoride can have an acute toxic effect. Doses of several milligrams of fluoride per kg of body weight may cause nausea, vomiting, and diarrhoea. Tetany and convulsion can occur, as well as cardiovascular disorders.
Increased risk of bone fracture and skeletal fluorosis (stiffness of joints and skeletal deformities) will only be observed in cases of very high chronic intake of fluoride.
Management:
Treatment and management should be symptomatic. In case of mild gastrointestinal overdose symptoms a small glass of milk to drink should be given to bind fluoride ion. It should be noted that gut decontamination is contraindicated. Charcoal is of no benefit.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
Pharmacotherapeutic group: caries prophylactic agents
ATC code: A01AA01
This product is a toothpaste in which the active ingredient is Sodium Fluoride present at a level of 0.619% which corresponds to 280 mg fluoride per 100 g paste.
Sodium fluoride applied topically after tooth eruption reduces caries by inhibiting demineralisation and promoting remineralisation of the tooth surface. It is effective on both enamel and exposed dentine.
5.2 Pharmacokinetic Properties
This product is not intended to be swallowed and therefore only minimal systemic exposure is expected.
5.3 Preclinical Safety Data
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction and development.
6. Pharmaceutical Particulars
6.1 List of Excipients
  • Glycerol (E 422)
  • Purified Water
  • Sorbitol, liquid (non-crystallizing) (E 420)
  • Silicas
  • Polyethylene glycol 600
  • Sodium lauryl sulphate
  • Sodium carboxymethylcellulose (E 467)
  • Mint Flavour
  • Titanium dioxide (E 171)
  • Sodium saccharin (E954)
6.2 Incompatibilities
Not applicable.
6.3 Shelf Life
3 years.
6.4 Special Precautions for Storage
Do not store above 25°C.
6.5 Nature and Contents of Container
75 ml polyethylene/aluminium/polyethylene laminated tube with a polypropylene screw closure. Pack sizes: 1 x 75ml tube or 2 x 75ml tubes.
6.6 Instructions for Use and Handling
Not applicable.
7. Marketing Authorisation Holder
  • Colgate-Palmolive (U.K.) Ltd
  • Guildford Business Park
  • Middleton Road
  • Guildford
  • Surrey GU2 8JZ
  • United Kingdom
8. Marketing Authorisation Number
PL 00049/0039
9. Date of First Authorisation/Renewal of the Authorisation
19/07/2006
10. Date of Revision of the Text
January 2015

1Biesbrock AR et al. Community Dent Oral Epidemiol 2001; 29: 382-389

2Tavss EA et al (2003) Am J Dent; 16: 369-374

Colgate Maximum Cavity Protection plus Sugar Acid Neutraliser